EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische Studie

Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis

Richard A Furie, Brad H Rovin, Jay P Garg, Mittermayer B Santiago, Gustavo Aroca-Martínez, Adolfina Elizabeth Zuta Santillán, Damaris Alvarez, Cleyber Navarro Sandoval, Alexander M Lila, James A Tumlin, Amit Saxena, Fedra Irazoque Palazuelos und 12 weitere

New England Journal of Medicine · 17.04.2025 · 392 (15) · 1471-1483

DOI: 10.1056/nejmoa2410965 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift New England Journal of Medicine, erschienen am 17.04.2025. Verfasst von Richard A Furie und 23 weiteren Autor:innen. Beteiligte Einrichtung: Division of Rheumatology, Northwell Health, Great Neck, NY. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Immunosuppressive Agents, Lupus Nephritis. Die Arbeit wurde bisher 290-mal zitiert (Crossref) und nennt 39 Literaturangaben. Gefördert von: F. Hoffmann–La Roche.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Obinutuzumab, a humanized type II anti-CD20 monoclonal antibody, provided significantly better renal responses than placebo in a phase 2 trial involving patients with lupus nephritis receiving standard therapy. METHODS: In a phase 3, randomized, controlled trial, we assigned adults with biopsy-proven active lupus nephritis in a 1:1 ratio to receive obinutuzumab in one of two dose schedules (1000 mg on day 1 and at weeks 2, 24, 26, and 52, with or without a dose at week 50) or placebo. All patients received standard therapy with mycophenolate mofetil, along with oral prednisone at a target dose of 7.5 mg per day by week 12 and 5 mg per day by week 24. The primary end point was a complete renal response at week 76, defined by a urinary protein-to-creatinine ratio of less than 0.5 (with protein and creatinine both measured in milligrams), an estimated glomerular filtration rate of at least 85% of the baseline value, and no intercurrent event (i.e., rescue therapy, treatment failure, death, or early trial withdrawal). Key secondary end points at week 76 included a complete renal response with a prednisone dose of 7.5 mg per day or lower between weeks 64 and 76 and a urinary protein-to-creatinine ratio lower than 0.8 without an intercurrent event. RESULTS: A total of 271 patients underwent randomization; 135 were assigned to the obinutuzumab group (combined dose schedules) and 136 to the placebo group. A complete renal response at week 76 was observed in 46.4% of the patients in the obinutuzumab group and 33.1% of those in the placebo group (adjusted difference, 13.4 percentage points; 95% confidence interval [CI], 2.0 to 24.8; P = 0.02). A complete renal response at week 76 with a prednisone dose of 7.5 mg per day or lower between weeks 64 and 76 was observed in more patients in the obinutuzumab group than in the placebo group (42.7% vs. 30.9%; adjusted difference, 11.9 percentage points; 95% CI, 0.6 to 23.2; P = 0.04), and a urinary protein-to-creatinine ratio lower than 0.8 without an intercurrent event was more common with obinutuzumab than with placebo (55.5% vs. 41.9%; adjusted difference, 13.7 percentage points; 95% CI, 2.0 to 25.4; P = 0.02). No unexpected safety signals were identified. More serious adverse events, mainly infections and events related to coronavirus disease 2019, occurred with obinutuzumab than with placebo. CONCLUSIONS: Among adults with active lupus nephritis, obinutuzumab plus standard therapy was more efficacious than standard therapy alone in providing a complete renal response. (Funded by F. Hoffmann-La Roche; REGENCY ClinicalTrials.gov number, NCT04221477.).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedImmunosuppressive AgentsLupus NephritisAdultFemaleHumansMaleYoung AdultCreatinineDouble-Blind MethodDrug Administration ScheduleDrug Therapy, CombinationGlomerular Filtration RateMycophenolic AcidPrednisoneProteinuriaInfusions, IntravenousDose-Response Relationship, DrugTreatment OutcomeUrinary Tract InfectionsGastroenteritisPneumonia

Substanzen

Antibodies, Monoclonal, HumanizedCreatinineImmunosuppressive AgentsMycophenolic AcidobinutuzumabPrednisone

Autor:innen und Institutionen

  • Division of Rheumatology, Northwell Health, Great Neck, NY.
  • Department of Internal Medicine, Ohio State University College of Medicine, Columbus.
  • Genentech, South San Francisco, CA.
  • Bahiana School of Medicine and Public Health, Salvador, Brazil.
  • Federal University of Bahia, Salvador, Brazil.
  • Clínica SER (Serviços Especializados em Reumatologia) da Bahia, Salvador, Brazil.

Förderung

  • F. Hoffmann–La Roche

Zitieren

APA

Furie, R. A., Rovin, B. H., Garg, J. P., Santiago, M. B., Aroca-Martínez, G., Zuta Santillán, A. E., Alvarez, D., Navarro Sandoval, C., Lila, A. M., Tumlin, J. A., Saxena, A., Irazoque Palazuelos, F., Raghu, H., Yoo, B., Hassan, I., Martins, E., Sehgal, H., Kirchner, P., Ross Terres, J., …, & REGENCY Trial Investigators (2025). Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. New England Journal of Medicine, 392(15), 1471-1483. https://doi.org/10.1056/nejmoa2410965

Vancouver

Furie RA, Rovin BH, Garg JP, Santiago MB, Aroca-Martínez G, Zuta Santillán AE, et al. Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis. New England Journal of Medicine. 2025;392(15):1471-1483. doi:10.1056/nejmoa2410965

BibTeX
@article{Furie2025,
  author = {Furie, Richard A and Rovin, Brad H and Garg, Jay P and Santiago, Mittermayer B and Aroca-Martínez, Gustavo and Zuta Santillán, Adolfina Elizabeth and Alvarez, Damaris and Navarro Sandoval, Cleyber and Lila, Alexander M and Tumlin, James A and Saxena, Amit and Irazoque Palazuelos, Fedra and Raghu, Harini and Yoo, Bongin and Hassan, Imran and Martins, Elsa and Sehgal, Himanshi and Kirchner, Petra and Ross Terres, Jorge and Omachi, Theodore A and Schindler, Thomas and Pendergraft, William F and Malvar, Ana and REGENCY Trial Investigators, REGENCY Trial Investigators},
  title = {Efficacy and Safety of Obinutuzumab in Active Lupus Nephritis},
  journal = {New England Journal of Medicine},
  year = {2025},
  volume = {392},
  number = {15},
  pages = {1471--1483},
  doi = {10.1056/nejmoa2410965}
}
Kostenlos starten →